Landmark Bio, a collective endeavor bringing together industry, academia, and research hospitals to accelerate development of next-generation genomic medicines, signed a multi-year strategic manufacturing agreement with Galapagos NV, a biotech company with operations in Europe and the U.S. Under the terms of the agreement, Landmark Bio will provide GMP manufacturing of clinical trial batches of Galapagos’ development programs of chimeric antigen receptor (CAR) T-cell therapies in hemato...